Emerging studies have shown that long noncoding RNA (lncRNA) TUG1 (taurine-upregulated gene 1) plays critical roles in multiple biological processes. However, the expression and function of lncRNA TUG1 in cerebral ischaemia/reperfusion injury have not been reported yet. In this study, we found that LncRNA TUG1 expression was significantly up-regulated in cultured MA-C cells exposed to OGD/R injury, while similar results were also observed in MCAO model. Mechanistically, knockdown of TUG1 decreased lactate dehydrogenase levels and the ratio of apoptotic cells and promoted cell survival in vitro. Moreover, knockdown of TUG1 decreased AQP4 (encoding aquaporin 4) expression to attenuate OGD/R injury. TUG1 could interact directly with miR-145, and down-regulation of miR-145 could efficiently reverse the function of TUG1 siRNA on AQP4 expression. Finally, the TUG1 shRNA reduced the infarction area and cell apoptosis in I/R mouse brains in vivo. In summary, our results suggested that lncRNA TUG1 may function as a competing endogenous RNA (ceRNA) for miR-145 to induce cell damage, possibly providing a new therapeutic target in cerebral ischaemia/reperfusion injury. K E Y W O R D S Aquaporin-4, cerebral ischaemia, lncTUG1, miR-145, reperfusion injury S U PP O RTI N G I N FO R M ATI O N Additional supporting information may be found online in the Supporting Information section. How to cite this article: Shan W, Chen W, Zhao X, et al. Long noncoding RNA TUG1 contributes to cerebral ischaemia/ reperfusion injury by sponging mir-145 to up-regulate AQP4 expression. J Cell Mol Med. 2020;24:250-259. https ://doi.
| INTRODUC TI ON
Ischaemia/reperfusion (I/R) is considered important for the recovery of ischaemic brain injury and also limits subsequent infarction development. 1 However, ischaemia/reperfusion induces apoptosis, inflammation and the overproduction of reactive oxygen species (ROS), thus leading to neuronal injury. 2 Thrombolytic therapy has been the only accepted treatment for cerebral I/R injury in clinics. 2, 3 However, this therapy inevitably leads to ischaemia/reperfusion injury (IRI) and its treatment effect is limited. Accumulating evidence shows that apoptosis and death of nerve cells after I/R are the main causes of aggravating brain injury. 4, 5 Therefore, it is important to develop novel therapeutic strategies to treat cerebral IRI.
In the human genome, only 2% of the DNA is translated into proteins, suggesting that the majority of the genome remains either un-transcribed or (more often) transcribed into non-protein-coding RNAs. 6 According to their length, non-protein-coding RNAs are divided into two groups, small and long noncoding RNAs. Long | 251 SHAN et Al. noncoding RNAs (lncRNAs) are longer than 200 nucleotides. They cannot be translated into proteins; therefore, initially, lncRNAs were considered as non-functional junk. However, currently, they are thought to participate in the regulation of protein expression. 7, 8 Taurine-upregulated gene 1 (TUG1), a 7.1-kb gene located at chr22q12.2, was initially identified as a transcript up-regulated in retinal cells treated with taurine. 9 Increasing evidence suggests that TUG1 is involved in the development of a variety of cancers, including laryngeal squamous cell carcinoma and ovarian cancer. 10, 11 It has been also reported that TUG1 was up-regulated in the brain of middle cerebral artery occlusion (MCAO) and oxygen-glucose deprivation (OGD)-treated SH-SY5Y cells, indicating the therapeutic potential of TUG1 in I/R. 12 However, there is limited knowledge on how TUG1 acts at the molecular level and its exact role in I/R.
Recently, many studies have demonstrated that lncRNAs regulate gene expression at various levels, including chromatin modification, transcriptional regulation and post-transcriptional regulation. 13 LncRNAs can act as competing endogenous RNAs (ceRNAs) to reduce the concentrations of microRNAs (miRNAs), resulting in inhibition of miRNA functions in cells. 14 For example, lncRNA TUG1 promotes cell proliferation and metastasis by negatively regulating miR-300 in gallbladder carcinoma. 15 In addition, TUG1 alleviates extracellular matrix accumulation via mediating microRNA-377 targeting of PPAR in diabetic nephropathy. 16 These results prompted us to explore the mechanism of TUG1 in cerebral I/R. Aquaporin-4 (AQP4) is mainly expressed in astrocyte, particularly on the end of astrocyte at the blood-brain barrier. 17 Early study has shown that AQP4 inhibition in mice reduces brain oedema after ischaemic stroke. 18 Evidence has revealed that AQP4 is involved in enhancing brain oedema and AQP4 inhibition reduced brain oedema and infarct volume after ischaemic. 19 Our previous studies also showed that AQP4 overexpression could aggravate astrocyte ischaemic/reperfusion injury. 20, 21 In the present study, we employed a MCAO model and MA-C cell oxygen-glucose deprivation and reperfusion (OGD/R) model to determine whether TUG1 expression was altered in cerebral IRI.
We found that TUG1 was significantly up-regulated after OGD/R treatment and in the MCAO model. Subsequent functional studies revealed that TUG1 silencing attenuated the OGD/R injury both in vitro and in vivo. Mechanistically, TUG1 acts as a miRNA sponge to positively modulate the expression of AQP4 by sponging miR-145.
Therefore, our study provides new insights into the molecular function of the TUG1/miR-145/AQP4 signalling pathway in the pathogenesis of cerebral IRI and highlights the potential of lncRNAs to act as new therapeutic targets in cerebral IRI.
| MATERIAL S AND ME THODS

| Primary cultures of cerebellar astrocytes
Primary mouse astrocytes were obtained from a post-natal day (PND) 7 cerebral cortex, as previously described. 22 Briefly, brain regions were dissected, mechanically dissociated and incubated with trypsin, followed by trituration, repeated washing and filtering.
After counting, cells were plated at a density of 10 7 cells in 75 cm 2 tissue culture flasks pre-coated with poly-D-lysine and grown in Dulbecco's modified Eagle's medium (DMEM; Gibco) containing 10% fetal bovine serum (FBS), 100 U/mL penicillin and 100 µg/mL streptomycin at 37°C in 5% CO 2 .
| Establishment of the OGD/R model and MCAO model
To simulate an in vitro ischaemic-like condition, MA-C cells were subjected to OGD. The culture medium was replaced with deoxygenated glucose-free DMEM, and cells were incubated in a hypoxic chamber containing 5% CO 2 , 1% O 2 and 94% N 2 for 6 hours. Subsequently, the MA-C cells were returned to glucose-containing DMEM under normal culture conditions for 24 or 48 hours for reoxygenation. The overall protocol is known as OGD/R treatment.
C57/BL6 male mice were used in this study. All animal experiment protocols were approved by the animal committee at Zhejiang University. Healthy adult C57BL/6 mice were injected with intraperitoneal anaesthesia (4% chloral hydrate). The left common carotid artery, internal carotid artery and external carotid artery were separated sequentially from the left lateral approach to the neck. A silicone cord was inserted from the common carotid artery to the middle cerebral artery. After 60 minutes of embolization, the cord was removed and ligated.
Mice were randomly divided into four groups: (a) Sham: threading without occlusion, followed by persistent perfusion (n = 5); (b) I/R group: 1 hour of ischaemia and 24 hours of reperfusion (n = 5);
(c) I/R + NC: mice were administrated with negative control shRNA (sh-NC; NC; 0.5 mg/kg, via intracerebroventricular injection) before ischaemia treatment (n = 5) and (d) I/R + TUG1 shRNA: mice were administrated with TUG1 shRNA (0.5 mg/kg, via intracerebroventricular injection) before ischaemic treatment (n = 5). TUG1 shRNA or sh-NC was injected into the right cerebral ventricle of mice. One day post-injection, MCAO operation was established.
| Transfection of TUG1 siRNA, miR-145 mimic, miR-145 inhibitor or AQP4 siRNA
To investigate the lncRNA TUG1's function in OGD/R-treated MA-C cells, miR-145 mimics, inhibitors, negative control miRNA, TUG1 siRNA, AQP4 siRNAs, or negative siRNA, or two of these treatments were transfected into cells at working concentrations 
| Real-time polymerase chain reaction
Total RNA was isolated from cultured primary astrocytes or ischaemic hemisphere from MCAO mice using the TRIzol reagent (Invitrogen) following the manufacturer's protocol, and the RNA concentration was measured spectrophotometrically. Single-stranded cDNA was synthesized using a cDNA synthesis kit (Takara) according to the manufacturer's procedures. RT-PCR assays were performed using Applied Biosystems SYBR Green Mix kits (Applied Biosystems). The following primers were used:
All experiments were repeated three times, and the results were normalized to the expression of actin or U6 mRNA. 
| Western blot analysis
| Lactate dehydrogenase assay
The death of MA-C cells was evaluated using a cytotoxicity lactate dehydrogenase (LDH) assay kit (DOJINDO) according to the manufacturer's protocol. Briefly, MA-C cells were cultured in 6-well plates, following OGD/R treatment and transfection. MA-C cells were collected, resuspended and cultured in 96-well plates in 37°C in CO 2 for the appropriate time. Then, 10 µL of Lysis Buffer was added and the cells were cultured at 37°C in CO 2 for 30 minutes. Working solution was then added at 100 µL per well, and the samples were cultured at room temperature in the dark. Stop solution (50 µL) was then added to each well, and LDH levels in the culture supernatant were analysed immediately by measuring the absorbance at 490 nm using a microplate reader. LDH levels in the control group were expressed as 100%, and the levels in other groups were normalized to this value. were then cultured 37°C for 30 minutes before washing twice with phosphate-buffered saline (PBS). Live cells were detected by excitation at 490 nm, and dead cells were detected by excitation at 545 nm using a microplate reader.
| Cell health assay
| TdT-mediated biotin-16-dUTP nick-end labelling assay
The TdT-mediated biotin-16-dUTP nick-end labelling (TUNEL) assay was performed using a One-Step TUNEL Apoptosis Assay kit (Roche) to detect apoptotic cells in the mouse brain. In brief, 4-μm-thick paraffin sections were deparaffinized, hydrated, treated with proteinase K for 20 minutes and subsequently incubated with a mixture of a fluorescently labelled solution of dUTP and the TdT enzyme at 37°C for 1 hour in a humidified atmosphere. As a positive control, sections were incubated with DNase I for 10 minutes at room temperature (25°C) before the fluorescent labelling procedure. Negative controls were incubated with dUTP for 10 minutes at room temperature (25°C). Subsequently, the samples were treated with diaminobenzidine, counterstained with haematoxylin (to identify the cell nuclei).
The cells were then dehydrated in a gradient ethanol series, vitrified with dimethylbenzene and mounted with neutral balsam.
| 2,3,5-Triphenyltetrazolium chloride measurement
Animals were anaesthetized with 4% chloral hydrate, and brain tissues were sectioned coronally and consecutively at 2-mm thick. Coronal brain slices were incubated in 1% 2,3,5-Triphenyltetrazolium chloride (TTC) buffer, at 37°C for 20 minutes. After incubation, the brain slices were fixed in 4% paraformaldehyde for 24 hours and then photographed. The red regions represented non-infarcted tissue regions, and pale white regions are infarcted tissue regions.
| Neurological function assessment
The severity of the injury of treated mice was assessed using a modified Bederson score as previously described. 23 The modified Bederson scores were as follows: 0, no deficit; mice with score 1, lost forelimb flexion; 2, as for 1, but plus decreased resistance to a lateral push; 3, indicated unidirectional circling; mice with score 4 displayed longitudinal spinning or seizure activity; mice with score 5 showed no movement.
Luciferase reporter assay
293T cells were seeded in a 24-well plate. After 24 hours, miR-145-5p mimics or miR-NC was cotransfected with TUG1-wt (wild type) or TUG1-mut (mutant) into 293T cells using Lipofectamine 3000 (Invitrogen), dual-luciferase reporter assay system (Promega) were applied at 48 hours after transfection according to the manufacturer's instructions. 
| Apoptosis assay
| Immunofluorescence
Immunofluorescence was used to identify astrocytes. Cells were washed with cold PBS, fixed in 4% paraformaldehyde for 15 minutes, blocked with 5% serum at 37°C for 60 minutes and incubated with a 1:300 dilution of anti-glial fibrillary acidic protein (GFAP) antibodies (#3670; CST) at 4°C overnight. After washing with PBS three times, the cells were incubated with a 1:100 dilution of a secondary antibody (#4409; CST) at 37°C for 2 hours. 2-(4-amidinophenyl)-1H-indole-6-carboxamidine (DAPI; Sigma-Aldrich; Merck KGaA) was used for nuclear staining at 37°C for 2 minutes, and the cells were then washed three times with PBS and observed using an inverted fluorescence microscope (Olympus Corp.).
| Statistical analysis
Statistical analysis was performed using GraphPad Prism 5.0 software (GraphPad Software). Data were presented as a mean ± standard deviation (SD). To compare the difference between two groups or multiple groups, a t test and one-way analysis of variance (ANOVA) were performed, respectively. A difference was considered significant at P < .05.
| RE SULTS
| TUG1 is highly expressed after OGD/R treatment
To investigate whether TUG1 expression was altered in cerebral IRI, Figure 1A ). Moreover, TUG1 levels were significantly up-regulated under OGD/R conditions compared with that under the control conditions (P < .05; Figure 1B) . These results suggested that the up-regulation of lncRNA TUG1 contributes to cerebral ischaemia injury.
Given that TUG1 is overexpressed in MA-C cells exposed to OGD/R treatment, we performed knockdown of TUG1 in vitro to investigate whether TUG1 plays a role in IRI. Three small interfering RNA (siRNAs) targeting the coding region of TUG1 (siTUG1-3)
were tested for their knockdown efficiency. Cells were transfected with siTUG1-1, siTUG1-2, siTUG1-3 or a negative control.
The efficiency of interference was verified by qRT-PCR ( Figure   S1 ). The effects of TUG1 on OGD/R were evaluated using LDH assays and cell health assays. Silencing of TUG1 significantly sup- 
| Knockdown of TUG1 attenuates the OGD/R injury by inhibiting the expression of AQP4
Our team has been studying AQP4 and brain tissue injury in the early stage and found that AQ P4 plays an important role in cerebral injury in stroke. 20, 21 This was confirmed in Figure S , which showed that knockdown of AQP4 inhibits cell apoptosis and LDH leakage, and increases cell health in OGD/R-treated MA-C cells. Therefore, we hypothesized that TUG1 might exert its function by regulating AQP4 expression. To confirm whether TUG1 regulates AQP4, MA-C cells were transfected with siTUG1-1, siTUG1-2, siTUG1-3 or the negative control. As expected, knockdown of TUG1 expression significantly decreased the accumulation of AQ P4 (Figure 2A ).
Next, to confirm whether AQP4 mediates the damage of caused by TUG1 to MA-C cells exposed to OGD/RX, the cells were transfected with siAQ P4, exposed to OGD/R, and then transfected with control, siTUG1-1, siTUG1-2 and siTUG1-3, respectively. OGD/R treatment enhanced LDH leakage and suppressed cell viability, whereas knockdown of AQP4 significantly attenuated the OGD/R treatment-induced damage. However, knockdown of TUG1 did not further mitigate the damage ( Figure 2B ). The efficiency of siAQP4 interference was verified by qRT-PCR ( Figure S1 ). In addition, after transfection with siAQP4, knockdown of TUG1 did not further decrease the OGD/R treatment-induced apoptosis ( Figure 2C ). These results indicated that TUG1 plays a role in cerebral IRI by regulating AQP4 expression.
| TUG1 directly interacts with mir-145 to regulate AQP4 protein expression
Bioinformatic analysis of miRNA recognition sequences in TUG1 was performed using miRcode. MiR-145 was identified as being capable of binding to complementary sequences in TUG1 ( Figure 3A) . To prove the prediction, we performed luciferase reporter assay. The results showed that TUG1-WT could significantly lower the luciferase activity in miR-145-5p group but had no significant effect on the luciferase activity of the miR-NC group ( Figure 3B ). To determine whether the expression of miR-145 is regulated by TUG1, we transfected MA-C cells with siTUG1-1, siTUG1-2 and siTUG1-3. After knockdown of TUG1, the mir-145 level was significantly up-regulated, indicating that TUG1 negatively regulates mir-145 ( Figure 3C ).
To investigate the regulatory effect of mir-145 on AQP4 expression, MA-C cells were transfected with a mir-145 mimic or mir-145 inhibitor. The mir-145 mimic decreased AQP4 levels, while the mir-145 inhibitor increased AQP4 levels ( Figure 3D ). OGD/R treatment significantly enhanced AQP4 expression, while the mir-145 mimic significantly suppressed the AQP4 expression induced by OGD/R treatment ( Figure 3E ). Taken together, these data indicated that knockdown of TUG1 increased the expression of miR145 and 
| Mir-145 inhibitor reverses the protective effect of TUG1 siRNA against OGD/R-induced injury in vitro
Considering the inhibitory action of TUG1 on miR-145 levels in MA-C cells, we further explored the role of miR-145 in the protective effects of the TUG1 siRNA against OGD/R-induced injury. Astrocytes were pretreated with the miR-145 inhibitor, transfected with untreated and siTUG1-1, siTUG1-2 or siTUG1-3, and then exposed to OGD/R. LDH, F I G U R E 2 Knockdown of TUG1 attenuates the OGD/R injury by inhibiting the expression of AQP4. A, AQP4 protein levels in MA-C cells transfected with short interfering RNAs siTUG1-1, siTUG1-2 and siTUG1-3 as assessed using by Western blotting assays. B, LDH leakage (left) and cell viability were measured using LDH and CCK8 assays, respectively. MA-C cells were transfected with siTUG1-1, siTUG1-2 and siTUG1-3 in 6-h OGD/24-h reoxygenation treatments. C, Flow cytometry assays were performed to show the cell apoptosis after cotransfection with AQP4 siRNA and siTUG1-1, siTUG1-2 and siTUG1-3 in 6-h OGD/24-h reoxygenation treatments. AQP4, aquaporin 4; OGD/R, oxygen-glucose deprivation and reperfusion; siRNA, short interfering RNA; TUG1, taurine-up-regulated gene 1 inhibitor + si-TUG1 did not decrease cell apoptosis, suggesting that the protective effect of TUG1 siRNA had disappeared ( Figure 4C-D) .
Next, siTUG1-1 was chosen for further experiments. Astrocytes were pretreated with siTUG1-1, transfected separately with untreated and mir-145 inhibitor, and then exposed to OGD/R TUG1 knockdown significantly reduced LDH leakage, whereas cotransfection of the miR-145 inhibitor + si-TUG1 did not reduce LDH leakage ( Figure 4E ). In addition, apoptosis assays showed that TUG1 knockdown significantly decreased cell apoptosis under OGD/R treatment, while cotransfection of the miR-145 inhibitor + si-TUG1 did not decrease cell apoptosis ( Figure 4F-G) . Collectively, these results demonstrated the TUG1 siRNA protects against cerebral IRI by upregulating mir-145 levels.
| In vivo, TUG1 shRNA reduces the infarction area and cell apoptosis in I/R mice brains
To demonstrate the protective role of TUG1 against brain I/R injury, we first established the MCAO model in mice and determined the effect of TUG1 on infarction area using TTC staining, with Sham, MCAO, MCAO + NC and MCAO + TUG1 shRNA groups. As shown in Figure 5A , the infarct region was observed in the brain of both MCAO and MCAO + NC groups. However, the infarct area was significantly reduced in the MCAO group + TUG1 shRNA group ( Figure 5B ). Meanwhile, we used the Bederson score to rate the functional neurological deficits in MCAO mice after transfection with or without TUG1 shRNA. The results showed that the Bederson score decreased significantly after TUG1 knockdown ( Figure 5C ).
Moreover, TUNEL analysis revealed that TUG1 knockdown could significantly decrease the rate of apoptosis in MCAO mice ( Figure 5D ).
Our data indicated that TUG1 knockdown effectively protects against brain tissue damage in MCAO model mice.
| D ISCUSS I ON
Although evidence has demonstrated the ectopic expression of lncRNA TUG1 in many cancers, 10, 11, 24 its expression and biological role in cerebral IRI remain uncharacterized. Our study confirmed that TUG1 expression was significantly higher after OGD/R treatment compared with that in the control group. High TUG1 expression was also found in MCAO model mice compared with the control group. Moreover, shRNA-mediated silencing of TUG1 reduced the infarction area and cell apoptosis in I/R mouse brains.
Together, these data support the concept that TUG1 is associated with cerebral IRI and functions as a positive regulator in IRI progression. A new mechanism has been proposed in which lncRNA H19 induces cerebral ischaemia-reperfusion injury 25 Aquaporin-4 (AQP4), a member of the water channel family, is mainly expressed in astrocytes, ependymal cells, soft meninges, choroid plexus and the nucleus of the lower mound in the brain. 17, 26 Increasing evidence indicates that AQP4 plays an important role in cerebral ischaemia/reperfusion. Combination therapy of Emodin and GRb1 had a neuroprotective effect via the down-regulation of AQP4 in cerebral ischaemia/reperfusion rats. 27 AQP4-null mice are protected from cellular (cytotoxic) brain oedema produced by water intoxication, brain ischaemia or meningitis. 28 Our previous studies showed AQP4 plays a role in cerebral ischaemic injury. 20, 21 MiR-29a ameliorated ischaemic injury of astrocytes in vitro by targeting AQP4, 20 and up-regulation of miR-130b protects against cerebral ischaemic injury also by targeting AQP4. 21 Therefore, we hypothesized that TUG1 exerts its function by regulating AQP4. First, knockdown of TUG1 decreased the accumulation of the AQP4 protein. Second, APQ4 silencing alleviated cellular damage. However, knockdown of TUG1 did not further mitigate the damage. Third, after transfection with siAQP4, knockdown of TUG1 did not further decrease the OGD/R treatment-induced apoptosis. The above data not only supported a pro-apoptosis role of AQP4 in cerebral ischaemic injury progression, but also revealed a novel mechanism by which an lncRNA induces cell damage by regulating AQP4 expression.
The mechanisms of action of lncRNAs include both transcriptional and post-transcriptional regulation. Recently, a new regulatory mechanism in which lncRNAs acting as ceRNAs to sponge miRNAs, thus participating in post-transcriptional processing, has been identified. 29 The miRNA sponge function of TUG1 was supported by the evidence generated in the present study. First, we predicted the interaction between TUG1 and miR-145 using bioinformatic analysis and found that TUG1 indeed contains a target site of miR-145. Second, after knockdown of TUG1, the mir-145 level was significantly up-regulated, indicating that TUG1 negatively regulates mir-145. Third, down-regulation of miR-145 level efficiently reversed the protective effect induced by the TUG1 siRNA. These results confirmed that TUG1 induces cell damage by regulating mir-145.
After confirming the positive relationship between TUG1 and AQP4, as well as the negative correlation between TUG1 and mir-145 during cerebral I/R injury, we also identified the downstream target of mir-145 in this mechanism. Overexpression of miR-145 via the mir-145 mimic decreased AQP4 accumulation, whereas down-regulation of mir-145 via the mir-145 inhibitor increased AQP4 levels.
In addition, the mir-145 mimic reversed the AQP4 expression in the presence of OGD/R. These analyses showed that TUG1 sponges miR-145 to induce cell damage by up-regulating AQP4. In fact, previous studies have shown that individual protein-coding genes can be regulated by multiple non-protein-coding RNAs, while one nonprotein-coding RNA can regulate multiple protein-coding genes. 30, 31 Thus, whether AQP4 could be regulated by other sponging lncRNAs, and whether TUG1 could function as a sponge lncRNA to affect expressions of other key regulators in cerebral IRI, requires further investigation.
| CON CLUS ION
In the present study, we identified TUG1 as a novel positive regulator in the pathogenesis of cerebral IRI. Moreover, our findings shed light on the interaction between TUG1 and miR-145 in IRI, and revealed that TUG1 positively regulates post-transcriptional expression of AQP4 by sponging miR-145 in cerebral IRI. Knockdown of TUG1 via siRNA decreased AQP4 expression, providing a novel therapeutic target for cerebral IRI.
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